First in-human, safety and preliminary efficacy study of (neo)adjuvant, modelbased, whole-body hyperthermia treatment in advanced solid cancer patients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients: Liquid biopsies.

被引：0
|
作者：
Gorbaslieva, Ivana [1 ]
Mustafa, Dana [2 ]
Colenbier, Robin [1 ]
Peeters, Marc [3 ]
Ysebaert, Dirk [3 ]
Saldien, Vera [3 ]
Brancato, Luigi [4 ]
Rudenko, Oleg [4 ]
Van den Bossche, Johan [4 ]
Bogers, John Paul [4 ]
机构：
[1] Univ Antwerp, Antwerp, Belgium
[2] Erasmus MC, Rotterdam, Netherlands
[3] Univ Antwerp Hosp, Antwerp, Belgium
[4] ElmediX, Mechelen, Belgium
来源：
CANCER RESEARCH | 2022年 / 82卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A023
引用
收藏
页码：169 / 169
页数：1
相关论文
共 4 条
  • [1] A monocentric, first-in-human (FIH), safety and preliminary efficacy study of (neo) adjuvant, model-based, whole-body hyperthermia (WBHT) treatment in advanced solid cancer patients or stage IV metastatic pancreatic adenocarcinoma patients
    Gorbaslieva, Ivana
    Peeters, Marc
    Ysebaert, Dirk
    Saldien, Vera
    Rudenko, Oleg
    Brancato, Luigi
    van den Bossche, Johan
    Bogers, Johannes
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] The MATTERS trial: A first-in-human study of whole-body hyperthermia in advanced solid cancer patients
    Gorbaslieva, I.
    Dankerlui, R.
    Ysebaert, D.
    Saldien, V.
    Vandamme, T.
    Brancato, L.
    Rudenko, O.
    Van den Bossche, L.
    Van den Bossche, J.
    Van den Cruys, K.
    Bogers, J.
    Peeters, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S76 - S76
  • [3] Preliminary safety, efficacy and immunogenicity results from a phase 1/2a study (DIRECT-01) of cancer neoantigen DNA vaccine VB10.NEO in patients with locally advanced or metastatic solid tumors
    Krauss, Jurgen
    Krackhardt, Angela
    Jaeger, Elke
    Williams, Anja
    Rafiyan, Reza
    Wold, Hedda
    Gerner, Lisa
    Sekelja, Monika
    Fredriksen, Agnete
    Schjetne, Karoline
    Axelsen, Mads
    Fredriksen, Agnete
    Wold, Hedda
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine/nab-paclitaxel as first-line (1L) treatment in patients with Claudin18.2-positive locally advanced unresectable or metastatic (LA/m) pancreatic cancer.
    Zhang, Yanqiao
    Zhang, Shu
    Gong, Jifang
    Zhang, Miao
    Liang, Xinjun
    Wang, Junye
    Li, Yun
    Jin, Zhaoyu
    Yang, Yaping
    Ding, Guoliang
    Tian, Chen
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 729 - 729
1